top of page

BioVenture VoiCes Episode 48: Blackstone's Kiran Reddy

1 hour ago
1 min read

Blackstone's Senior Managing Director Kiran Reddy describes his early life and education, and the impact that patient care has had on his approach to investing. He describes notable investments in neuroscience, and a stop at Biogen, before returning to investing at Clarus, which was acquired by Blackstone. He recalls the unique opportunity he saw when a company with the resources of Blackstone decided to go big into life sciences.




Chapters

Intro and early life - 1:20

First business experience - 8:46

Patient care - 12:34

Third Rock - 21:02

Biogen - 38:19

Clarus and Praxis - 43:08

Neuroscience R&D - 46:36

Blackstone's commitment to life sciences - 52:45

Personal life - 1:06:04

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page